Top 5 Biotech Stocks for 2018



Biotech is a notoriously risky business. Many biotechnology products do not produce the desired results consistently, while others fail to gain acceptance in the marketplace. Of course, when a biotech product succeeds, investors can make a lot of money.

Celgene Corporation (CELG)

Celgene focuses on cancer and inflammatory diseases.Тhe first half of 2018, but given Celgene's solid long-term track record, the recent declines may represent a buying opportunity.

Average Volume: 6,678,603
Market Cap: $60.4 billion
P/E Ratio (TTM): 23.67
EPS (TTM): $3.52
Dividend and Yield: N/A (N/A)

Gilead Sciences, Inc. (GILD)

Gilead has been growing at a rate of around 30% for five years. The company is a leader in HIV treatments and has a successful drug for treating hepatitis C. A look at the stock chart shows that Gilead entered a declining price channel starting around May 2016. The shares put in a bottom at around $64, then broke sharply upward in late June 2017. The stock had additional high-volume breakouts at the beginning of September 2017 and then again to start the new year, reaching a 52-week high of nearly $90 toward the end of January 2018.

Average Volume: 7,198,649
Market Cap: $98.846 billion
P/E Ratio (TTM): 28.92
EPS (TTM): $2.63
Dividend and Yield: $2.28 (3.03%)


Exelixis, Inc. (EXEL)

It has anti-tumor drugs as well as treatments for kidney cancer. The company has routinely delivered positive surprises on earnings. Exelixis stock broke sharply upward out of the base in late June 2017, and after seeing some volatility during the later part of the year, it moved up strongly once again in December.The stock continued to see some ups and downs to start 2018 before declining sharply in late February on a lackluster response to fourth quarter earnings.

Average Volume: 4,572,853
Market Cap: $6.415 billion
P/E Ratio (TTM): 26.71
EPS (TTM): $0.81
Dividend and Yield: N/A (N/A)


Enzo Biochem, Inc. (ENZ)

Enzo offers therapies for cancer, diabetes, cardiovascular disease and infectious diseases. The stock entered an uptrend in March 2016 and started forming a new base in December 2016. Enzo shares broke out in early March 2017 and then saw a second breakout on June 11, 2017. The stock is now in a new base that began forming in late June of last year, and it continued to tick downward over the first half of 2018. With a market cap of approximately $239 million, Enzo represents the smallest company on our list, which could suggest even more volatility in a sector that is already known for its ups and downs.


Average Volume: 151,242
Market Cap: $238.659 million
P/E Ratio (TTM): N/A
EPS (TTM): -$0.09
Dividend and Yield: N/A (N/A)

AbbVie Inc. (ABBV)

AbbVie is the maker of Humira, which treats autoimmune issues. AbbVie shares surged in September 2017, and at the end of that month, the company settled a dispute with Amgen Inc. (AMGN), successfully delaying the competitor's launch of a biosimilar version of Humira. The company experienced a setback in July 2018 when it announced disappointing results in a trial of Imbruvica for the treatment of lymphoma, sending the stock price downward to current levels just below $95.

Average Volume: 8,155,779
Market Cap: $143.775 billion
P/E Ratio (TTM): 23.88
EPS (TTM): $3.98
Dividend and Yield: $3.84 (3.96%)


Read more:

If you think, we can improve that section,
please comment. Your oppinion is imortant for us.
WARNING: Any news, opinions, research, data or other information contained within this website is provided as general market commentary and does not constitute investment or trading advice. Varchev Finance Ltd. expressly disclaims any liability for any lost principal or profits which may arise directly or indirectly from the use of or reliance on such information. Varchev Finance Ltd. may provide information, quotes, references and links to or from other sites and blogs and other sources of economic and market information as an educational service to its clients and prospects and does not endorse the opinions or recommendations of the sites, blogs or other sources of information.
Varchev Finance


25 Canada Square, Level 33, office 50, Canary Wharf London, E14 5LQ +44 20 3608 6256

Universal numbers

World Financial Markets - 0700 17 600    Varchev Exchange - 0700 115 44

Varchev Finance Ltd is registered in the FCA (FINANCIAL CONDUCT AUTHORITY) with a passport in the United Kingdom: FCA, United Kingdom - registration number: 494 045, which allows provision of financial services in the United Kingdom.

Varchev Finance Ltd strictly comply with the statutes of the European directive MiFID (Markets in Financial Instruments). targeting increased efficiency, transparency and uniformity of financial instruments.
Varchev Finance Ltd is authorized and regulated by the Financial Supervision Commission - Sofia, Bulgaria: License number RG-03-02-05 / 15.03.2006

The information on this site is not intended for distribution or use by any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation.


CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 63,41% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.

chat with dealer
chat with dealer
Cookies policy